Total Payments
$92,371
2024 Payments
$34,859
Companies
12
Transactions
79
Medicare Patients
732
Medicare Billing
$91,729
Payment Breakdown by Category
Consulting$41,489 (44.9%)
Travel$22,410 (24.3%)
Other$21,473 (23.2%)
Research$5,220 (5.7%)
Food & Beverage$1,780 (1.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $41,489 | 15 | 44.9% |
| Travel and Lodging | $22,410 | 17 | 24.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $21,473 | 6 | 23.2% |
| Unspecified | $5,220 | 9 | 5.7% |
| Food and Beverage | $1,780 | 32 | 1.9% |
Payments by Type
General
$87,150
70 transactions
Research
$5,220
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $40,225 | 21 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $18,925 | 28 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $11,246 | 10 | $0 (2023) |
| Genentech USA, Inc. | $10,215 | 6 | $0 (2023) |
| Merck Sharp & Dohme LLC | $4,420 | 2 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $3,983 | 1 | $0 (2024) |
| Genentech, Inc. | $1,950 | 1 | $0 (2022) |
| Intera Oncology, Inc | $644.52 | 4 | $0 (2024) |
| Boston Scientific Corporation | $450.00 | 1 | $0 (2023) |
| Nevro Corp. | $133.26 | 2 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $34,859 | 13 | F. Hoffmann-La Roche AG ($25,957) |
| 2023 | $26,679 | 24 | F. Hoffmann-La Roche AG ($12,368) |
| 2022 | $11,728 | 11 | AstraZeneca Pharmaceuticals LP ($7,646) |
| 2018 | $71.12 | 2 | Ethicon US, LLC ($71.12) |
| 2017 | $19,033 | 29 | Bayer HealthCare Pharmaceuticals Inc. ($18,925) |
All Payment Transactions
79 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/04/2024 | JAZZ PHARMACEUTICALS INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,982.50 | General |
| 10/28/2024 | Merck Sharp & Dohme LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| 10/28/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 10/25/2024 | Intera Oncology, Inc | INTERA (Device) | Consulting Fee | Cash or cash equivalent | $375.00 | General |
| Category: ONCOLOGY | ||||||
| 09/13/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | Travel and Lodging | Cash or cash equivalent | $11,409.12 | General |
| Category: BioOncology | ||||||
| 09/13/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | Consulting Fee | Cash or cash equivalent | $3,293.33 | General |
| Category: BioOncology | ||||||
| 09/13/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | Consulting Fee | Cash or cash equivalent | $3,040.00 | General |
| Category: BioOncology | ||||||
| 09/13/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | Consulting Fee | Cash or cash equivalent | $3,040.00 | General |
| Category: BioOncology | ||||||
| 09/13/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | Travel and Lodging | Cash or cash equivalent | $1,523.86 | General |
| Category: BioOncology | ||||||
| 09/13/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | Food and Beverage | In-kind items and services | $74.25 | General |
| Category: BioOncology | ||||||
| 09/13/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | Food and Beverage | In-kind items and services | $29.45 | General |
| Category: BioOncology | ||||||
| 09/03/2024 | Intera Oncology, Inc | INTERA (Device) | Consulting Fee | Cash or cash equivalent | $125.00 | General |
| Category: ONCOLOGY | ||||||
| 07/23/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | Consulting Fee | Cash or cash equivalent | $3,546.67 | General |
| Category: BioOncology | ||||||
| 12/18/2023 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,611.00 | General |
| 10/20/2023 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | Travel and Lodging | In-kind items and services | $6,068.90 | General |
| Category: BioOncology | ||||||
| 10/20/2023 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | Travel and Lodging | In-kind items and services | $919.15 | General |
| Category: BioOncology | ||||||
| 10/20/2023 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | Food and Beverage | In-kind items and services | $160.29 | General |
| Category: BioOncology | ||||||
| 07/11/2023 | Genentech USA, Inc. | Tecentriq (Biological) | Food and Beverage | In-kind items and services | $5.60 | General |
| Category: BioOncology | ||||||
| 06/30/2023 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $1,524.99 | Research |
| Study: Tecentriq plus Avastin Following Curative Resection in Patients at High Risk of Recurrence • Category: BioOncology | ||||||
| 06/30/2023 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $1,082.09 | Research |
| Study: Tecentriq plus Avastin Following Curative Resection in Patients at High Risk of Recurrence • Category: BioOncology | ||||||
| 06/30/2023 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $911.14 | Research |
| Study: Tecentriq plus Avastin Following Curative Resection in Patients at High Risk of Recurrence • Category: BioOncology | ||||||
| 06/30/2023 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $515.36 | Research |
| Study: Tecentriq plus Avastin Following Curative Resection in Patients at High Risk of Recurrence • Category: BioOncology | ||||||
| 06/30/2023 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $369.07 | Research |
| Study: Tecentriq plus Avastin Following Curative Resection in Patients at High Risk of Recurrence • Category: BioOncology | ||||||
| 06/30/2023 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $279.05 | Research |
| Study: Tecentriq plus Avastin Following Curative Resection in Patients at High Risk of Recurrence • Category: BioOncology | ||||||
| 06/30/2023 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $246.05 | Research |
| Study: Tecentriq plus Avastin Following Curative Resection in Patients at High Risk of Recurrence • Category: BioOncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Tecentriq plus Avastin Following Curative Resection in Patients at High Risk of Recurrence | F. Hoffmann-La Roche AG | $5,220 | 9 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 182 | 238 | $104,338 | $22,094 |
| 2022 | 4 | 195 | 274 | $115,512 | $25,315 |
| 2021 | 5 | 188 | 267 | $98,668 | $27,563 |
| 2020 | 5 | 167 | 216 | $87,015 | $16,757 |
Total Patients
732
Total Services
995
Medicare Billing
$91,729
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 69 | 106 | $49,184 | $11,065 | 22.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 66 | 84 | $28,896 | $6,122 | 21.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 34 | 34 | $22,576 | $4,245 | 18.8% |
| 76998 | Ultrasonic guidance during surgery | Facility | 2023 | 13 | 14 | $3,682 | $661.92 | 18.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 80 | 120 | $41,280 | $8,723 | 21.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 47 | 47 | $31,208 | $6,662 | 21.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 41 | 54 | $25,056 | $5,787 | 23.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 14 | 33 | $11,088 | $2,670 | 24.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 13 | 20 | $6,880 | $1,473 | 21.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 81 | 109 | $37,496 | $8,194 | 21.9% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 13 | 47 | $7,520 | $7,520 | 100.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 41 | 41 | $27,224 | $5,793 | 21.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 23 | 26 | $12,264 | $2,896 | 23.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 18 | 32 | $11,008 | $2,573 | 23.4% |
| 76998 | Ultrasonic guidance during surgery | Facility | 2021 | 12 | 12 | $3,156 | $587.16 | 18.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 73 | 99 | $34,056 | $5,801 | 17.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 19 | 34 | $11,424 | $2,880 | 25.2% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 27 | 27 | $14,391 | $2,606 | 18.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 11 | 12 | $7,848 | $1,970 | 25.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 13 | 13 | $8,632 | $1,787 | 20.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 24 | 31 | $10,664 | $1,713 | 16.1% |
About Dr. Adam Yopp, MD
Dr. Adam Yopp, MD is a Surgical Oncology healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/16/2008. The National Provider Identifier (NPI) number assigned to this provider is 1992965735.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Adam Yopp, MD has received a total of $92,371 in payments from pharmaceutical and medical device companies, with $34,859 received in 2024. These payments were reported across 79 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($41,489).
As a Medicare-enrolled provider, Yopp has provided services to 732 Medicare beneficiaries, totaling 995 services with total Medicare billing of $91,729. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Surgical Oncology
- Location Dallas, TX
- Active Since 06/16/2008
- Last Updated 02/20/2019
- Taxonomy Code 2086X0206X
- Entity Type Individual
- NPI Number 1992965735
Products in Payments
- Tecentriq (Biological) $48,540
- Stivarga (Drug) $18,925
- IMFINZI (Biological) $9,607
- TECENTRIQ (Biological) $1,900
- INTERA (Device) $500.00
- TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial) (Device) $450.00
- Intera 3000 Hepatic Artery (Device) $144.52
- Omnia (Device) $133.26
- Epclusa (Drug) $108.43
- CERTUS 140 MICROWAVE ABLATION SYSTEM (Device) $71.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Surgical Oncology Doctors in Dallas
Dr. Peter Beitsch, M.d, M.D
Surgical Oncology — Payments: $63,607
Surgical Oncology $63,607
Glen Balch, Md, MD
Surgical Oncology — Payments: $13,007
Surgical Oncology $13,007
Ann Leitch, Md, MD
Surgical Oncology — Payments: $3,062
Surgical Oncology $3,062
Archana Ganaraj, Md, MD
Surgical Oncology — Payments: $2,224
Surgical Oncology $2,224
Lisa Anderson, Md, MD
Surgical Oncology — Payments: $2,099
Surgical Oncology $2,099
Dr. Jeffrey Lamont, M.d, M.D
Surgical Oncology — Payments: $1,985
Surgical Oncology $1,985